Connect with:
Saturday / December 7. 2024
HomePosts Tagged "Dr K Anand Kumar"

The VNN vaccine developed by CIBA can prevent vertical transmission of the disease to the offsprings and prevent mortality in fingerlings.

Indian Immunologicals Limited (IIL), a leading vaccine manufacturer, has announced partnership with Central Institute of Brackishwater Aquaculture (CIBA), Chennai, an Indian Council of Agricultural Research (ICAR) Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish developed by CIBA.

IIL ventured into aqua business in October 2022 by launching products for aquaculture health market dealing with pond management and fish or shrimp gut management and subsequently announced commercial development of fish vaccines with ICAR’s CIFE, Mumbai and CIFA, Bhubaneswar. India is the 3rd largest fish producer in the global sphere and more than 65 per cent of India’s fish is through Inland Fisheries and Aquaculture. The main constraint to aquaculture globally, however, is disease with an estimate that 20 per cent of all cultured aquatic animals are lost because of infectious diseases, amounting to >10 billion USD in losses annually on a global scale.

Viral nervous necrosis (VNN) or viral encephalopathy and retinopathy (VER) is an acute viral disease affecting several species of marine, brackishwater and freshwater fishes. The disease causes up to 100 per cent mortality in larval and early juvenile stages. Adult fish when infected, is asymptomatic, but can transmit the virus to the offspring through eggs and gonadal fluids.

Speaking on the occasion, Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said, “IIL is the first in India to get to fish vaccines. We are covering different kind of fishes (fresh water, brackish water, etc.) and culture conditions (pond, cage culture, etc.) and are aware of the challenges associated with being the first, having been in similar situations for many other livestock vaccines. We are working at multiple fronts in defining pathways for commercial development of fish vaccines in India”.

Dr. Priyabrata Pattnaik, Deputy Managing Director, Indian Immunologicals Limited added “IIL as a leading “One Health” organization is committed to developing vaccines for different fish pathogens with a long-term strategic objective of reducing use of antibiotics in aquaculture there by antimicrobial resistance in environment”.

Dr. Kuldeep K. Lal, Director, ICAR-CIBA said “viral nervous necrosis is a major threat for brackishwater aquaculture. The VNN vaccine developed by CIBA can prevent vertical transmission of the disease to the offsprings and prevent mortality in fingerlings. The vaccine can play a significant role in controlling the loss due to VNN in India and other Asian countries”.

Aquaculture in India suffers economic losses due to infections caused by several bacterial, viral, fungal, and other aetiological agents. Currently these infections are being managed by anti-infectives and other conventional measures with varying degree of success. With the rising concern pertaining on anti-microbial resistance (AMR) and chemical free food products both at global and domestic platforms, there is a growing need for better control measures against these infections. Currently there is no fish vaccines available in India on a commercial scale to prevent aquaculture infections.

The VNN vaccine developed by CIBA can

With an investment of approximately Rs 700 crores the proposed facility is expected to create more than 750 direct and indirect jobs.

Indian Immunologicals Limited (IIL), one of India’s leading biotechnology companies dedicated to manufacturing and supplying life-saving vaccines, has started construction of its new greenfield veterinary vaccine facility to manufacture the Foot and Mouth Disease Vaccine (FMD-Vac) as well as Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD+HS-Vac) in Hyderabad’s Genome valley.

This brand-new unit will have a BSL3 facility for the manufacture of Drug substances and a Fill-Finish capability for the production of both drug products FMD vaccine and the FMD+HS vaccine.

Telangana State Industrial Infrastructure Corporation Ltd (TSIIC), a Government of Telangana undertaking had allotted the land to IIL at Biotech Park, Phase III, Karkapatla, Siddipet district in Telangana. The proposed facility has a capacity of 150 million doses/annum of FMD vaccine or FMD+HS vaccine each. With an investment of approximately Rs 700 crores the proposed facility is expected to create more than 750 direct and indirect jobs.

Indian Immunologicals Limited is a subsidiary of the National Dairy Development Board (NDDB). In its more than 40 years of journey, IIL has carved a niche space as a leading “One Health” organization, manufacturing animal and human vaccines. IIL also exports its products to more than 60 countries across the globe.

 Speaking on the occasion, Dr Meenesh Shah, Chairman of NDDB and IIL said, “IIL continues to fulfil the purpose for which it was created by NDDB as a world class vaccine manufacturer. This new vaccine manufacturing facility in Hyderabad is dedicated to the nation and will certainly aid in the eradication of Foot and Mouth Disease in our country. IIL’s ability to discover and manufacture affordable vaccines has saved the exchequer several thousand crores of rupees”.

Dr K Anand Kumar, Managing Director, IIL said, “We are the largest supplier of FMD vaccine to Government of India’s prestigious Livestock Health Disease Control Programme (LHDCP). We are in an exponential growth phase and expected to grow 40 per cent this year alone. In order to sustain the momentum, IIL is seriously considering making additional investments in building infrastructure within India and in other emerging geographies including Africa in a manner to develop tools that will help in control and eradication of diseases.”

With an investment of approximately Rs 700